Martin Frenzel
- Oncology top 0.5%
- HER2/EGFR in Cancer Research 15
- Cancer-related Molecular Pathways 8
- Cancer Treatment and Pharmacology 6
- Lung Cancer Research Studies 3
- Pulmonary and Respiratory Medicine top 0.5%
- Advanced Breast Cancer Therapies 24
- Genetics top 0.5%
- Chronic Lymphocytic Leukemia Research 1
- Cancer Research top 1%
- Pathology and Forensic Medicine top 10%
-
- Ion channel regulation and function 1
- Hedgehog Signaling Pathway Studies 1
Martin Frenzel
28 papers receiving 4.0k citations
Hit Papers
Peers
Comparison fields: 5 of 82
- Oncology 3.2k
- Pulmonary and Respiratory Medicine 3.7k
- Genetics 998
- Cancer Research 1.3k
- Pathology and Forensic Medicine 125
Countries citing papers authored by Martin Frenzel
This map shows the geographic impact of Martin Frenzel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Frenzel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Frenzel more than expected).
Fields of papers citing papers by Martin Frenzel
This network shows the impact of papers produced by Martin Frenzel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Frenzel. The network helps show where Martin Frenzel may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Martin Frenzel, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 3 | |
| 2 | 2020 | 2 | |
| 3 | 2020 | 2 | |
| 4 | MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancerbreakdown → | 2019 | 407 |
| 5 | The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2breakdown → | 2019 | 590 |
| 6 | 2018 | 48 | |
| 7 | MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancerbreakdown → | 2017 | 1125 |
| 8 | MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancerbreakdown → | 2017 | 490 |
| 9 | MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapybreakdown → | 2017 | 1103 |
| 10 | 2017 | 13 | |
| 11 | 2017 | 10 | |
| 12 | 2016 | 72 | |
| 13 | 2016 | 52 | |
| 14 | 2016 | 3 | |
| 15 | 2015 | 8 | |
| 16 | 2015 | 12 | |
| 17 | 2014 | 26 | |
| 18 | 2014 | 35 | |
| 19 | 2012 | 1 | |
| 20 | 2008 | 26 |
About Martin Frenzel
Martin Frenzel is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine, Genetics and Computer Networks and Communications, having authored 28 papers that have together received 4.1k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (24 papers), HER2/EGFR in Cancer Research (15 papers), Cancer-related Molecular Pathways (8 papers), Cancer Treatment and Pharmacology (6 papers), Lung Cancer Research Studies (3 papers), Ion channel regulation and function (1 paper), Chronic Lymphocytic Leukemia Research (1 paper) and Hedgehog Signaling Pathway Studies (1 paper). The work is most often cited by research in Oncology (3.2k citations), Pulmonary and Respiratory Medicine (3.7k citations), Genetics (998 citations), Cancer Research (1.3k citations) and Pathology and Forensic Medicine (125 citations). Martin Frenzel has collaborated with scholars based in United States, Spain and Japan. Frequent co-authors include Masakazu Toi, Susana Barriga, Joohyuk Sohn, Nawel Bourayou, Matthew P. Goetz, Angelo Di Leo, George W. Sledge, Antonio Llombart‐Cussac, Tammy Forrester and Norikazu Masuda. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Annals of Oncology, npj Breast Cancer and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.